Journal Information
Vol. 12. Issue 4.
Pages 359-367 (July - August 2006)
Share
Share
Download PDF
More article options
Vol. 12. Issue 4.
Pages 359-367 (July - August 2006)
Artigo Original\Original Article
Open Access
Papel das citocinas proliferativas TGF-β e VEGF no derrame pleural pós-revascularização do miocárdio
The proliferative cytokines TGF-β and VEGF in pleural effusions post-coronary artery bypass graft
Visits
4182
António M.S. Chibante1,
Corresponding author
chibante@domain.com.br

Correspondência/Correspondence to: António M S Chibante, Centro de Investigações Pneumológicas RJ, Rua Sorocaba, 477 sala 601 Rio de Janeiro, Brasil, Cep: 22.271-110 E
, Marcelo Alexandre C. Vaz2, Francisco Vargas Suso2
1 Serviço de Cardiopneumologia, Hospital Gaffrée-Guinle. Univesidade do Rio de Janeiro/Cardiopulmonology Unit, Hospital Gaffrée-Guinle. Universidade do Rio de Janeiro
2 Serviço de Pneumologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo/Pulmonolgy Unit, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
This item has received

Under a Creative Commons license
Article information
Resumo

A cirurgia de revascularização do miocárdio envolve o acometimento, tanto do pericárdio como da pleura, conduzindo ao favorecimento de processos inflamatórios responsáveis pelo desenvolvimento de derrames nestes compartimentos.

Objectivo: Estudar o comportamento das citocinas proliferativas TGF-β (factor beta de transformação do crescimento) e VEGF (factor de crescimento do endotélio vascular) nos líquidos de 16 transudatos e de 43 derrames pleurais de doentes submetidos a cirurgias de revascularização do miocárdio provenientes do Instituto de Coração e do Serviço de Pneumologia da Universidade do São Paulo nos intervalos de 2, 24 e 48 horas de pós-operatório.

Resultados: O derrame pleural pós-revascularização do miocárdio é um exsudato mobilizador de TGF-β e VEGF no pós-operatório imediato. Os níveis de TGF-β apresentam-se elevados nas primeiras 2 horas para caírem progressivamente até se aproximarem dos valores dos transudatos ao fim de 48 horas, enquanto o VEGF se inicia com níveis elevados já nas primeiras 2 horas com tendência a aumento pelo menos até 48 horas de pós-operatório.

Conclusões: O TGF-β parece comportar-se como elemento gatilho sobre a célula mesotelial pleural para a liberação de VEGF no desenvolvimento de derrame pleural nas cirurgias de revascularização do miocárdio.

Rev Port Pneumol 2006; XII (4): 359-367

Palavras-chave:
Inflamação
citocinas
derrame pleural
revascularização do miocárdio
Abstract

Coronary artery bypass graft (CABG) surgeries can impact on the pericardium and pleural space, leading to inflammation which can cause effusion.

Aim: To study the role of the proliferative cytokines TGF-β and VEGF in the fluids of 16 transudates and 43 pleural effusions of patients who underwent CABG at the Heart Unit and Pulmonology Unit of the University Hospital of São Paulo. Levels of cytokines were assessed 2, 24 and 48 hours post-surgery.

Results: The pleural effusion after CABG is an exsudative mobilizer of TGF-β and VEGF cytokines immediately after surgery. The TGF-β concentrations were elevated 2 hours after surgery but started to fall soon after, reaching transudate levels after 48 hours. VEGF levels were high in the first 2 hours post surgery and tended to maintain the same concentrations for at least 48 hours after surgery.

Conclusions: Based on the results obtained, TGF-β is a cytokine that seems to work as a trigger, leading the pleural mesothelial cell to express VEGF a cause of pleural effusion in CABG surgeries.

Rev Port Pneumol 2006; XII (4): 359-367

Key-words:
Inflammation
cytokines
pleural effusions
coronary artery bypass grafting
Full text is only aviable in PDF
Bibliografia/Bibliography
[1.]
F.S. Vargas, A. Cukier, W. Hueb, L.R. Teixeira, R.W. Light.
Relationship between pleural effusions and pericardial involvement after myocardial revascularization.
Chest, 105 (1994), pp. 1738-1752
[2.]
R.W. Light.
Pleural effusions after coronary artery bypass graft surgery.
Curr Opin Pulm Med, 8 (2002), pp. 308-311
[3.]
F.S. Vargas, K.K. Vezhimi, F.F. Jatene, M. Terra-Filho, W. Hueb, A. Cukier, R.W. Light.
Acute pleuropulmonary complications detected by computed tomography following myocardial revascularization.
Rev Hosp Clin Fac Med São Paulo., 57 (2002), pp. 135-142
[4.]
C.A. Dinarello.
Proinflammatory Cytokines.
Chest, 118 (2000), pp. 503-508
[5.]
C. Kroegel, V.B. Anthony.
Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy.
Eur Respir J, 10 (1997), pp. 2411-2418
[6.]
J.P. Areno, J.P. McCarteney, J. Eggerstedt, W. Grafton, R. George.
Persistent pleural effusions following coronary bypass surgery.
Chest, 114 (1998), pp. 311-314
[7.]
Y.C. Lee, Vaz Mac, K.A. Ely, et al.
Symptomatic persistent post-coronary artery bypass graft pleural effusion requiring treatment-clinical and histologic features.
Chest, 119 (2001), pp. 795-800
[8.]
C.L. Chung, C.H. Chen, J.R. Sheu, Y.C. Chen, S.C. Chang.
Proinflammatory cytokines, transforming growth factorbeta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Chest, 128 (2005), pp. 690-697
[9.]
B.M. Kelly, J.J. Nicholas, R. Chhablani, C.J. Kavinsky.
The postpericardiotomy syndrome as a cause of pleurisy in rehabilitation patients.
Arch Phys Med Rehabil, 81 (2000), pp. 517-518
[10.]
De Souza Pereira.
Morphofunctions study of rat pleural mesothelial cells exposed to low frequency noise.
Aviat Space Environ Med, 70 (1999), pp. A78-A85
[11.]
K.N. Michailova.
Electronmicroscopic observations on the visceral and parietal rat’s pleura after contralateral pneumonectomy.
Eur J Morphol, 39 (2001), pp. 47-56
[12.]
K.A. Mohammed, N. Nasreen, J. Hardwick, C.S. Logie, C.E. Patterson, V.B. Anthony.
Bacterial induction of pleural mesothelial monolayer barrier dysfunction.
AmJ Physiol Lung Cell Mol Physiol, 281 (2001), pp. 119-125
[13.]
Y.C. Gary-Lee, D. Melkerneker, P.J. Thompson, W.R. Light, K.B. Lane.
Transforming growth factor beta induces VEGF elaboration from pleural mesothelial cell in vivo and in vitro.
Am J Respir Crit Care Med, 165 (2002), pp. 88-94
[14.]
M. Weatherhead, G. Antunes.
Chemotherapeutic management of malignant pleural effusion.
Expert Opin Pharmacother, 5 (2004), pp. 1233-1242
[15.]
Y.C. Gary-Lee, K.B. Lane.
The many faces of transforming growth factor- beta in pleural diseases.
Curr Opin Pulm Med, 7 (2001), pp. 173-179
[16.]
C.S. Grove, Y.C. Lee.
Vascular endothelial growth factor: the key mediator in pleural effusion formation.
Curr Opin Pulm Med, 8 (2002), pp. 294-301
[17.]
Y. Aoki, G. Tosato.
Vascular endothelial growth factor/ vascular permeability factor in the pathogenesis of primary effusion lymphomas.
Leuk Lymphoma, 41 (2001), pp. 229-237
[18.]
I. Kishiro, D. Kato, D. Fuse, T. Yoshida, S. Machida, N. Kaneko.
Clinical significance of vascular endothelial growth factor in patient with primary lung cancer.
Respirology, 7 (2002), pp. 93-98
[19.]
R. Naim, E. Tolnay, K.M. Mueller, C. Kuhnen.
Co-expression of VEGF, c-Met and HGF/SF in secondary pleural tumors.
Int J Mol Med, 14 (2004), pp. 787-791
[20.]
K.A. Mohammed, N. Nasreen, J. Hardwick, R.D. Van Horn, K.L. Sanders, V.B. Antony.
Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression.
[21.]
W.G. Roberts, G.E. Palade.
Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.
J Cell Sci, 108 (1995), pp. 2369-2379
[22.]
C.S. Grove, Y.C. Lee.
Vascular endothelial growth factor: the key mediator in pleural effusion formation.
Curr Opin Pulm Med, 8 (2002), pp. 294-301
[23.]
A.M.S. Chibante.
Análise do processo inflamatório agudo no líquido pleural pós-cirurgias de revascularização do miocárdio.
(2004),
Copyright © 2006. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?